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In total, 5,607 voluntary community-based HIV tests were carried out in 2019: 
• By test method, 2,813 tests (50%) were carried out using rapid point-of care test methods 
and 2,794 (50%) were carried out using laboratory-based methods 
• 92 people had a positive/reactive HIV test, corresponding to a 1.6% test reactivity rate 
• By test setting, the rate was highest in asylum/direct provision settings (3.6%), and at non-
governmental organisation (NGO) headquarters (1.1%)  
 
Demographic data was available for 4,756 (85%) tests:  
• By gender, the test reactivity rate was higher in females (2.2%) than in males (0.5%) 
• By key population group, the rate was highest among migrants coming from countries of 
high HIV prevalence (7.2%), and among men who have sex with men (MSM) (0.6%) 
• Twenty-three people were subsequently identified as having been previously diagnosed with 
HIV 
 
Excluding 23 people who were subsequently identified as having been previously diagnosed 
with HIV, the test reactivity rate was 0.5%: 
• By gender, the rate was higher in females (0.9%) than in males (0.4%) 
• By key population group, the rate was highest among migrants coming from countries of 
high HIV prevalence (3.1%), and among MSM (0.5%) 
 
Key points 
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Introduction  
Monitoring voluntary community-based HIV testing (VCBT) is essential for understanding the 
trends in community HIV reactive rates and for determining whether people most at risk of HIV 
infection are being reached. This report presents a summary of the results of VCBT in Ireland in 
2019, for data received up to 10 September 2020.  
 
Data on VCBT has been collated nationally since June 2018, for testing carried out since 1 
January 2017. This work has oversight from a multisectoral steering group; see Appendix A for 
membership of the group.  
 
The Health Protection Surveillance Centre (HPSC) partners with a number of 
organisations/programmes that provide VCBT services in Ireland. Participants in VCBT 
monitoring submit data to HPSC on a quarterly basis. A small anonymised disaggregated 
dataset is collated, in line with European Centre for Disease Prevention and Control (ECDC) 
recommendations [1]. Eight organisations/programmes participated in the monitoring process in 
2019, including all seven that provided data in 2018 and one new data provider. The list of data 
providers in 2019 is presented in Appendix B.   
 
Methods  
VCBT services are provided free of charge in a range of settings in Ireland. There are two 
methods in routine practice for HIV testing; rapid point of care testing (POCT) and laboratory-
based testing, these methods are further described in the Technical notes.  
 
The completeness of data in 2019 is provided in Appendix C. Of the eight participating 
organisations/programmes, seven provided disaggregate data, including data on previous HIV 
diagnosis and demographic characteristics. One organisation (Balseskin Reception Centre) 
could not provide disaggregate data and instead provided the number of HIV tests and the 
number of people that had a positive test result.   
  
The denominator used to calculate HIV test reactivity rate is of all tests carried out, not of 
individuals tested, as some people may have tested more than once during 2019. 
 
The results are presented as HIV test reactivity rate; this can also be called HIV testing 
prevalence rate or HIV seropositivity rate. 
 
Results  
In total, 5,607 community-delivered HIV tests were reported to HPSC in 2019. Of those, 2,813 
tests (50%) were carried out using rapid POCT methods and 2,794 (50%) were carried out 
using laboratory-based test methods. Ninety-two people had a reactive/positive HIV test, 
corresponding to a 1.6% test reactivity rate.  
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Seven out of eight participating organisations/programmes could provide data on whether or not 
a client/patient was subsequently identified as having been previously diagnosed HIV positive. 
Twenty-three people were subsequently identified as having been previously diagnosed with 
HIV. Excluding those 23, the test reactivity rate was 0.5%.  
 
i. Test setting  
Table 1 presents the number of positive/reactive HIV tests and test reactive rate by test setting. 
The highest proportion of tests were carried out in asylum/direct provision settings (n=1,961, 
35%), followed by non-governmental organisation (NGO) headquarters (n=1,097, 20%) and 
Bar/club settings (n=1,009, 18%). The test reactivity rate was highest in asylum/direct provision 
settings (3.6%), and at NGO headquarters (1.1%).  
 
Of the 1,961 tests in asylum or direct provision settings, 1,110 were NGO delivered (Safetynet 
n=1,028, SHC n=59, GOSHH n=23), and 851 were HSE delivered (Balseskin Reception 
Centre). For Safetynet testing exclusively in direct provision settings (i.e. excluding testing as 
part of the Irish Refugee Protection Programme (IRPP) and the Family Reunification 
Humanitarian Admission Programme (FRHAP)), the test reactivity rate was 3.5% (1.3% 
excluding 16 people who were later identified as previously diagnosed HIV positive).  
 
Table 1 Number of positive/reactive HIV tests and test reactivity rate (%) by test setting, voluntary 
community-based testing in Ireland, 2019    
All 
tests 
Positive 
/Reactive 
tests 
Test 
reactive 
rate 
Test 
reactive 
rate 
excluding 
people 
previously 
diagnosed 
HIV 
positive  
N N % % 
Asylum/direct provision settings (NGO and HSE delivered testing)     
NGO testing in asylum/direct provision settings excluding Balseskin 1110 25 2.3 0.8 
Balseskin Reception Centre (HSE delivered testing) 851 45 5.3 - 
Other settings (NGO delivered testing)     
NGO headquarters 1097 12 1.1 0.7 
Bar/club 1009 4 0.4 0.2 
LGBT community resource centre 464 3 0.6 0.6 
Emergency accommodation/homeless ID screening 340 0 0.0 0.0 
Addiction service/resource centre 197 2 1.0 0.5 
Sauna/sex-on-premises venue 143 1 0.7 0.7 
Other* 396 0 0.0 0.0 
Total excluding Balseskin Reception Centre 4756 47 1.0 0.5 
Total including Balseskin Reception Centre 5607 92 1.6 - 
-The number of people subsequently identified as previously diagnosed HIV positive in Balseskin is not available.  
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*Other includes colleges, festivals, community groups, general workspaces, prison services and other/unknown 
settings. 
 
The number of tests and test reactivity rates by test method and by testing modality are 
presented in Appendix D and Appendix E, respectively,  
 
ii. Demographic characteristics  
Demographic characteristics were provided by seven participating organisations/programmes 
(4,756 tests), and could not be provided by one organisation (Balseskin Reception Centre).  
 
Table 2 provides a demographic summary of people tested and of those with reactive tests. HIV 
test reactivity rate should be interpreted with caution due to low numbers tested (<100) among 
some demographic subgroups.  
 
By gender, the test reactivity rate was higher among females (2.2%) than males (0.5%). The 
median age among those with positive/reactive tests was 34 years.  
 
Among the 47 people who had a positive/reactive test, 41 (87%) were born abroad, four (9%) 
were born in Ireland, and region of origin was unknown for two (4%). By region of origin, the test 
reactivity rate was highest among people born in sub-Saharan Africa (7%).  
 
Individuals could be reported as part of one or more key population/at-risk group. The test 
reactivity rate was 7.2% among migrants coming from countries of high HIV prevalence, and it 
was 0.6% among men who have sex with men (MSM).  
 
A demographic summary of HIV test reactivity rate by previous HIV diagnosis is provided in 
Appendix F. Excluding 23 people who were later identified as having been previously diagnosed 
with HIV, the test reactivity rate was 0.5%. By gender, the rate among people newly diagnosed 
with HIV was higher in females (0.9%) than in males (0.4%). By key population group, the rate 
was highest among migrants coming from countries of high HIV prevalence (3.1%), and among 
MSM (0.5%). The median age among those newly diagnosed with HIV (28 years) was lower 
than the median age among those that were previously diagnosed with HIV (38 years).  
 
Balseskin Reception Centre is Ireland’s largest asylum accommodation centre and provides 
specialist medical and nurse delivered health screening for international protection applicants 
arriving to Ireland for the first time. As disaggregate data could not be provided, Balseskin could 
not be included in the demographic analysis. In 2019, 3,328 people seeking asylum in Ireland 
were accommodated in Balseskin, of which 1,578 were invited for holistic screening, 1,222 
accepted this invite, and 851 were screened for HIV. Of those who were screened for HIV in 
Balseskin, 45 (5.3%) had a positive test result, all of whom were coming from countries in sub-
Saharan Africa. Balseskin reported that the majority of those with a positive HIV test were 
previously diagnosed HIV positive in Africa before arrival to Ireland and already on antiretroviral 
drugs (ARVs). All 45 were linked to HIV care and treatment services in Ireland. 
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Table 2 HIV test reactivity rate (%) and demographic characteristics, voluntary community-based testing 
in Ireland, 2019 (n=4,756) [Excludes testing at Balseskin Reception Centre]   
    All tests Positive/ 
reactive 
tests 
Test 
reactivity 
rate 
    N N % 
Total   4756 47 1.0 
First time 
testing for 
HIV 
Yes 1183 8 0.7 
No 2323 13 0.6 
Unknown 1250 26 2.1 
Gender 
identity* 
Male 3502 19 0.5 
Female 1225 27 2.2 
Trans male 6 0 0.0 
Trans female 6 1 16.7 
Other/Unknown 17 0 0.0 
Age in years (median, range) 31 (17-99) 34 (19-56) 
 
Age group  17-24 926 5 0.5 
25-29 927 11 1.2 
30-39 1310 16 1.2 
40-49 625 9 1.4 
50-59 256 4 1.6 
60+ 111 0 0.0 
Unknown 601 2 0.3 
Region of 
origin 
Ireland 1930 4 0.2 
Latin America 514 4 0.8 
Sub-Saharan Africa 512 34 6.6 
Central or Eastern Europe 505 1 0.2 
Western Europe 463 1 0.2 
North Africa and Middle East 405 0 0.0 
South and South East Asia 207 0 0.0 
East Asia and Pacific 26 1 3.8 
Other** 97 0 0.0 
Unknown 97 2 2.1 
Key 
population 
group^ 
Men who have sex with men 2044 13 0.6 
Sex with a person of opposite sex  1437 5 0.3 
Migrant coming from a country of high HIV 
prevalence 
459 33 7.2 
People who have ever injected drugs 199 0 0.0 
Sex workers/escorts 27 1 3.7 
*Gender identity refers to a person’s internal sense of themselves (how they feel inside) as being male, female, 
trans male, trans female or something else. This may be different or the same as a person’s assigned sex at birth. 
Further information and resources can be found at the website of Transgender Equality Network Ireland 
(www.teni.ie). 
**Other Includes Australia & New Zealand, Caribbean, and North America. 
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^Individuals could be reported as part of one or more key population/at-risk groups. Countries of high HIV 
prevalence are countries with HIV prevalence >1% in the adult population, as per the UNAIDS 2014 The Gap 
Report.  
Discussion  
Overall, 5,607 community-based HIV tests were reported to HPSC in 2019, a 16% increase on 
the number reported in 2018 (n=4,846). Among the seven organisations/programmes that 
reported data in both years (i.e. excluding data from one new data provider in 2019), the 
increase in testing was also 16%, demonstrating continued expansion of existing VCBT 
programmes and initiatives in Ireland [2].  
 
Test reactivity rates overall and among specific key population groups such as migrants coming 
from countries of high HIV prevalence, and MSM, highlight the importance of sustained targeted 
VCBT services to ensure vulnerable groups continue to be reached.  
 
The high test reactivity rate in other key population groups such as sex workers (3.7%) and 
transgender people (8.3%) should be interpreted with caution due to low numbers tested, but 
should be continued to be monitored closely considering high rates among sex workers (3.6%) 
and transgender people (2.0%) also reported by the ‘HIV community-based testing practices in 
Europe’ (COBATEST) network in 2018 [3].  
 
Data on VCBT in other countries is limited. In the United Kingdom, HIV test reactivity rate in 
2018 is available for the national HIV self-sampling scheme (0.9%), and for the community 
HIV testing survey (0.4%) [4]. Data on VCBT provided by the COBATEST network (data 
submitted by 45 COBATEST members from 20 European countries) for 2018 shows the 
proportion of clients with reactive HIV screening test results (1.1%) is similar to the HIV test 
reactive rate in Ireland in 2019.  
In contrast to the COBATEST network 2018 results, in which the HIV test reactive rate was 
higher in males (1.4%) than in females (0.5%), the HIV test reactive rate in Ireland in 2019 was 
higher in females (2.2%) than in males (0.5%). Of the 27 females that had positive/reactive HIV 
test results in Ireland in 2019, 26 were born in countries in sub-Saharan Africa and region of 
origin was unknown for one. Of the 27 females, 16 were subsequently identified as previously 
diagnosed HIV positive (14 were previously diagnosed HIV positive abroad, and the place of 
previous diagnosis was unknown for two), and 11 were not previously diagnosed with HIV.  
 
There is currently no cost-effectiveness threshold for HIV testing in community settings. The 
VCBT reactivity rate in 2019 exceeds the recommended seropositivity threshold deemed to be 
cost effective for routinely offering HIV testing in hospital settings (0.1%) [5].    
 
Data quality improved considerably in 2019, thanks to the efforts of the data providers. This was 
evident in the completeness of data for numerous variables (e.g. for rapid POCT the 
completeness of data on age increased from 64% in 2018 to 98% in 2019).  
 
One organisation (ACET Ireland) was able to provide data for the first time, following 
commencement of their new VCBT initiative towards the end of 2019. Other new initiatives 
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included the relaunch of the Dublin-based MSM rapid testing programme in early 2020 as 
MPOWER, a peer-led and community-based response to the sexual health and wellbeing needs 
of gay and bisexual men.  
 
Improvements were also made to the dataset in 2019, with the addition of the variable ‘If test 
result positive/reactive, patient/client previously diagnosed HIV positive?’, with answer options 
differentiating between previous diagnosis in Ireland and previous diagnosis abroad. This has 
allowed for a better understanding of the data. Work is ongoing among NGOs to encourage all 
service users to communicate their HIV status before they test and to understand reasons for 
not disclosing HIV status and testing when already known. 
 
The variable ‘First time testing for HIV’ was completed for 74% of VCBT in 2019, improving the 
completeness of this variable may be important in the future in light of UNAIDS guidance on 
Global AIDS monitoring in 2020 which highlighted the importance of being able to disaggregate 
tests by previous testing history [6].  
 
Completeness of two variables ‘If positive/reactive HIV test, confirmation test positive?’ and ‘If 
positive/reactive HIV test, patient linked to HIV care and treatment services?’ were suboptimal. 
NGOs do not routinely collect this data therefore consideration may be given to removing these 
variables from the dataset in the future.  
 
The test reactivity rate was by far the highest in asylum/direct provision settings, particularly in 
Balseskin Reception Centre (5.3%), though the rate excluding people previously diagnosed HIV 
positive could not be determined for this centre. Balseskin was unable to provide disaggregate 
data and could not be included in the analysis of demographic characteristics. The HIV test 
reactivity rate excluding people previously diagnosed HIV positive could be determined for 
Safetynet testing in direct provision settings, and it was high, at 1.3%.  
 
This report is not inclusive of all HIV testing in asylum/direct provision settings, as not all HSE 
testing sites are currently included in HIV testing monitoring. NGO delivered testing in 
asylum/direct provision settings is included in the monitoring system, but the location of testing 
could not be provided for 1,028 (93%) of NGO delivered HIV tests in asylum/direct provision 
settings; in the absence of this information it is not possible to explore the representativeness of 
data on HIV testing in asylum/direct provision settings in Ireland.    
 
HIV testing in other settings including primary care, STI clinics, prisons, self-sampling and self-
testing, is not currently monitored nationally in Ireland. Work to determine the feasibility of 
monitoring HIV testing in some of these other settings commenced towards the end of 2019 but 
progress has been challenging in 2020 due to the COVID-19 pandemic, which resulted in 
reduced HIV/STI services across Ireland and a reallocation of resources at HPSC due to added 
pressures on surveillance. Expanding HIV testing monitoring is important work and HPSC 
hopes to continue this in future.    
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Technical notes  
1. Percentages are rounded to the nearest integer.  
2. There are two methods in routine practice for HIV testing: 
i. Testing carried out by a medical provider, involving venepuncture and laboratory-based 
methods which test for HIV antibody and p24 antigen simultaneously [5] 
ii. Testing carried out by a lay provider (a trained volunteer or staff member who 
administers a rapid point-of-care test (POCT) and refers a reactive test to a confirmatory 
testing service). The INSTI® Rapid (one-minute) HIV testing kit (with fingerstick blood) 
was used for all rapid POCT in this study. The accuracy of the INSTI® HIV-1 Antibody 
test (≥99.0%) meets the FDA established requirements for approval of a rapid HIV test 
device [7]. Data on confirmatory testing was available for 77% (n=10) of reactive POCT 
in 2019; of those there were no false positives reported. 
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Appendices  
Appendix A Membership of the Community HIV Testing Monitoring Steering Group (2020) 
Name Organisation 
Derval Igoe (Chair) HSE Health Protection Surveillance Centre (HPSC) 
Melissa Brady HSE Health Protection Surveillance Centre  
Erin Nugent HIV Ireland 
Adam Shanley HIV Ireland and the MPOWER programme 
Caroline Hurley HSE Sexual Health and Crisis Pregnancy Programme (SHCPP) 
Margaret Fitzgerald HSE National Social Inclusion Office  
Evan Murphy HSE Community Health Organisation (CHO 9)  
Emma Coughlan Mobile Health and Screening Unit, Safetynet Primary Care  
Richard Carson, 
Yvon Luky  
AIDS Care Education & Training (ACET) Ireland 
Cillian Flynn  Gender, Orientation, Sexual Health, HIV (GOSHH) 
Joe McDonagh  Sexual Health West (formerly AIDS West) 
Catherine Kennedy Sexual Health Centre  
Former member Niall Mulligan HIV Ireland 
Former member Maitiú ó Tuathail Mobile Health and Screening Unit, Safetynet Primary Care 
 
 
Appendix B List of data providers in 2019, HIV community testing monitoring  
 Organisation/Programme 
1 HIV Ireland (Eccles Street, Dublin and Red Door Project, Drogheda) 
2 MPOWER programme (formerly KnowNow Dublin) 
3 Gender, Orientation, Sexual Health, HIV (GOSHH) 
4 Sexual Health Centre  
5 Sexual Health West (formerly AIDS West) 
6 Safetynet Primary Care Mobile Health and Screening Unit (MHSU) 
7 AIDS Care Education & Training (ACET) Ireland 
8 Balseskin Reception Centre (HSE CHO Area 9) (aggregate data provided) 
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Appendix C Data completeness, HIV community testing monitoring 2019 (n=4,756) [Excludes Balseskin 
Reception Centre] 
  All tests Positive/reactive tests  
  n complete % complete n complete % complete 
Total tests  4756 - 47 -  
First time testing for HIV 3506 73.7 21 44.7 
Gender identity 4739 99.6 47 100.0 
Age group 4155 87.4 45 95.7 
Region of origin 4659 98.0 45 95.7 
Key population/at-risk group 3920 82.4 47 100.0 
If test result positive/reactive, patient/client 
previously diagnosed HIV positive? 
- - 45 95.7 
If positive/reactive HIV test, confirmation 
test positive? 
- - 20 42.6 
If positive/reactive HIV test, patient linked to 
HIV care and treatment services? 
- - 18 38.3 
 
 
Appendix D Number of positive/reactive HIV tests and test reactivity rate (%) by test method and 
service type, voluntary community-based testing in Ireland, 2019 (n=5,607)  
  All tests Positive/reactive 
tests 
Test reactivity 
rate 
 N N % 
Rapid POCT programme (lay provider) 2813 13 0.5 
STI/health screening service (medical provider) 2794 79 2.8 
 
 
Appendix E Number of positive/reactive HIV tests and test reactivity rate (%) by testing modality, 
voluntary community-based testing in Ireland, 2019 (n=5,607)   
  All tests Positive/reactive 
tests 
Test reactivity 
rate 
 N N % 
Mobile testing (e.g., through vans or  
temporary testing facilities)* 
2392 8 0.3 
VCBT centres not within a health facility 
 setting (e.g. NGO headquarters)*  
1250 14 1.1 
Asylum/direct provision settings 1961 70 3.6 
Other/unknown 4 0 0.0 
*Excludes asylum/direct provision settings 
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Appendix F HIV test reactivity rate (%) and demographic characteristics among people who had a positive/reactive HIV test, by previous HIV 
diagnosis, voluntary community-based testing in Ireland, 2019 (n=47) [Excludes testing at Balseskin Reception Centre]   
  
  
  
  
  
  
Previously diagnosed 
HIV positive 
Not previously 
diagnosed HIV positive 
Unknown 
Positive/ 
Reactive 
tests 
Test 
reactivity 
rate 
Positive/ 
Reactive 
tests 
Test 
reactivity 
rate 
Positive/ 
Reactive 
tests 
Test 
reactivity 
rate 
N % N % N % 
Total 23 0.5 22 0.5 2 0.0 
First time 
testing for 
HIV 
Yes 2 0.2 5 0.4 1 0.1 
No 4 0.2 8 0.3 1 0.0 
Unknown 17 1.4 9 0.7 0 0.0 
Gender 
identity* 
Male 6 0.2 11 0.3 2 0.1 
Female 16 1.3 11 0.9 0 0.0 
Trans female 1 16.7 0 0.0 0 0.0 
Age in years (median, range) 38 (26-56) 28 (22-54) 24 (19,29) 
Age group  17-24 0 0.0 4 0.4 1 0.1 
25-29 3 0.3 7 0.8 1 0.1 
30-39 10 0.8 6 0.5 0 0.0 
40-49 6 1.0 3 0.5 0 0.0 
50-59 2 0.8 2 0.8 0 0.0 
60+ 0 0.0 0 0.0 0 0.0 
Unknown 2 0.3 0 0.0 0 0.0 
Region of 
origin 
Ireland 1 0.1 3 0.2 0 0.0 
Latin America 1 0.2 2 0.4 1 0.2 
Sub-Saharan Africa 20 3.9 14 2.7 0 0.0 
Central or Eastern Europe 0 0.0 1 0.2 0 0.0 
Western Europe 0 0.0 1 0.2 0 0.0 
East Asia and Pacific 0 0.0 1 3.8 0 0.0 
Unknown 1 1.0 0 0.0 1 1.0 
Key 
population 
group^ 
Men who have sex with men 3 0.1 8 0.4 2 0.1 
Sex with a person of opposite sex  2 0.1 3 0.2 0 0.0 
Migrant coming from a country of high HIV prevalence 19 4.1 14 3.1 0 0.0 
Sex workers/escorts 1 3.7 0 0.0 0 0.0 
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*Gender identity refers to a person’s internal sense of themselves (how they feel inside) as being male, female, trans male, trans female or something else. 
This may be different or the same as a person’s assigned sex at birth. Further information and resources can be found at the website of Transgender Equality 
Network Ireland (www.teni.ie). 
^Individuals could be reported as part of one or more key population/at-risk groups. Countries of high HIV prevalence are countries with HIV prevalence >1% in 
the adult population, as per the UNAIDS 2014 The Gap Report.  
 
